Dupilumab, un nouveau médicament contre l’asthme Article d' Agnès Roux paru le 28 mai 2013 Un nouveau traitement expérimental contre l'asthme montre des résultats prometteurs.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Appelé dupilumab, il est développé par deux entreprises pharmaceutiques, l'une américaine et l'autre française. Le prestigieux New England Journal of Medicine vient de rendre compte de deux ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.“Dupilumab, a human monoclonal antibody ...

Paris et Tarrytown (New York). Le 21 mai 2023. Les résultats positifs d’un essai de phase III évaluant l’utilisation expérimentale de Dupixent ® (dupilumab), comparativement à un placebo ...

• Dupilumab comes as a pre-filled syringe which has to be injected under the skin as a subcutaneous injection. • Before injecting dupilumab, it is necessary to allow the medication to come to ...

Dupilumab is a "major advance for EoE that has to find its place but should be looked at with optimism and what I call tempered expectations," Philip Katz, MD, professor of medicine in the ...

MISSISSAUGA, ON, le 18 août 2020 /CNW/ - Sanofi Canada a annoncé aujourd'hui l'approbation par Santé Canada d'une nouvelle indication de DUPIXENT MD (dupilumab injectable) comme traitement d ...

MISSISSAUGA, ON, le 23 févr. 2021 /CNW/ - Sanofi Canada a annoncé aujourd'hui que Santé Canada a approuvé DUPIXENT MD (dupilumab injectable) dans le traitement des enfants âgés de six à 11 ...

"DUPILUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A ...